Enterprise Value

103.2M

Cash

40.98M

Avg Qtr Burn

-1.881M

Short % of Float

9.52%

Insider Ownership

9.78%

Institutional Own.

14.08%

Qtr Updated

09/30/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
ELFABRIO (Pegunigalsidase alfa )(PRX-102) Details
Genetic disorder, Rare genetic disease

Approved

Update

Elelyso® (taliglucerase alpha) Details
Genetic disorder, Rare genetic disease

Approved

Quarterly sales

PRX-115 Details
Chronic refractory gout

Phase 1

Data readout

Alidornase alfa (PRX-110) Details
Genetic disorder, Rare genetic disease, Cystic fibrosis

Failed

Discontinued

OPRX-106 Details
Inflammatory disease, Bowel disorder

Failed

Discontinued